Canada: Pharma In Brief - Federal Court Of Appeal Weighs In On Section 8 Damage Quantification

Cases: Apotex Inc. v. Sanofi-Aventis et al, 2014 FCA 68 and Teva Canada Limited v. Sanofi-Aventis Canada Inc. et al., 2014 FCA 67

Drug: ALTACE® (ramipiril)

Nature of cases: Appeal(s) in respect of the quantification of damages under Section 8 of the PM(NOC) Regulations

Date of decision: March 14, 2014


On March 14, 2014, the Federal Court of Appeal released two decisions with respect to proceedings commenced pursuant to section 8 of the Patented Medicines (Notice of Compliance) Regulations (the "PM(NOC) Regulations) in relation to Sanofi-Aventis' drug ALTACE® (ramipril). The first decision (2014 FCA 69) related to the quantification of damages for Teva Canada Limited ("Teva") under section 8 of the PM(NOC) Regulations (the "Teva Action") while the second decision( 2014 FCA 68) related to the quantification of damages for Apotex Inc. ("Apotex") in its case (the "Apotex Action").

These decisions represent the first time that the Federal Court of Appeal has fully considered issues related to the framework for awarding compensation under section 8 of the PM(NOC) Regulations. With strong dissenting opinions on some of the key issues at stake, some or all of the issues raised in these decisions may well be considered by the Supreme Court of Canada. As such, they represent the current, but possibly not the definitive, state of the law on the method of quantifying damages under section 8 of the PM(NOC) Regulations.

The Federal Court Decision(s) under Appeal

On May 23, 2012, Madam Justice Snider rendered decisions in actions commenced by Teva and Apotex pursuant to section 8 of the PM(NOC) Regulations against Sanofi-Aventis and related companies ("Sanofi"). Teva and Apotex claimed damages resulting from the delayed market entry for their generic ramipril products as a result of unsuccessful prohibition proceedings initiated by Sanofi. For a summary of the Federal Court decisions under Appeal, please see our previous publication.

Justice Snider's "stepped-methodology" for quantifying section 8 damages was not at issue on appeal. Instead, the parties focused on select aspects of the legal framework under which section 8 compensation may be determined.

Section 8 claimants are not entitled to 100% of the generic market

The Court held that in assessing damages under the PM(NOC) Regulations, it must consider the position the generic manufacturer would have occupied if it had not been prevented from receiving its NOC. Apotex and Teva argued that the trial judge erred in holding that they would have faced competition in the hypothetical market from other generics or an authorized generic. The Court flatly rejected the argument that section 8 claimants would not have faced competition from other generic entrants or authorized generics in the hypothetical world. The presence of other generic market entrants is a relevant issue to be taken into consideration.

On the evidence, the Court found no palpable or overriding error in the trial judge's finding in the Teva Action that Sanofi would have been able to launch an authorized generic at the beginning of the Teva liability period. However, in the Apotex Action, the Court found that the trial judge erred in finding that Teva would have entered the hypothetical market during the section 8 liability period.

Generic entry must factor in the operation of the Regulations

The majority of the Court (per Sharlow JA: Dawson JA concurring) held that all generic entrants are subject to the scheme of the PM(NOC) Regulations. As a result, when assessing damages, the behaviour of competing generic drug manufacturers in the hypothetical market must be considered. The majority of the Court held that the legal requirement to deliver notice(s) of allegation pursuant to the PM(NOC) Regulations before manufacturing a generic version of a drug would make a "surprise" generic launch unlikely in the hypothetical world.

Justice Mainville, in dissent, agreed with the majority's rejection of the trial judge's analysis, but differed with respect to the rationale and the appropriate methodology. Mainville J.A. held that the trial judge's methodology would "invariably" lead to windfalls for generic manufacturers pursuing actions under section 8 and would be inconsistent with general principles of compensatory damages. Mainville J.A. held that once a generic drug manufacturer is deemed to have received an NOC in the hypothetical world absent the PM(NOC) Regulations, other generic manufacturers should be presumed to be in a position to receive a NOC subject only to the delays and timelines set out in the Food and Drug Regulations.

Double ramp-up

The majority of the Court held that Apotex and Teva were not entitled to damages for a "double ramp-up" based on the reasoning in Apotex Inc. v. Merck Canada Inc., 2009 FCA 187 ("Alendronate"). In Alendronate, the Court held that to compensate a generic manufacturer for lost sales during the actual ramp-up period would have the effect of recognizing a loss suffered after the section 8 liability period. The majority of the Court acknowledged that rejecting the double ramp-up would represent a windfall for Sanofi, but noted that this was an inevitable consequence of the Governor-in-Council's decision to limit section 8 damages to losses incurred within the defined period.

Mainville J.A., in dissent, agreed with the reasoning of Justice Phelan in Apotex v. Takeda Canada Inc., 2013 FC 1237 and would have exercised his discretion under s. 8(5) to exclude the "ramp up" in the real world so as to avoid double counting in the hypothetical market.

Compensation for unapproved indications

Sanofi argued that Teva should not be entitled to compensation for any losses suffered in respect of unapproved indications (i.e., the HOPE indications). The Court held that the trial judge had the discretion to include these sales in assessing the amount of compensation under subsection 8(5) of the PM(NOC) Regulations, but emphasized that sales related to unauthorized indications may be precluded in other cases, if appropriate.

Lost business value

The Court characterized Teva's claim for "lost business value" as analogous to a claim for "lost future profits" which is precluded based on the reasoning in Alendronate.

Lost indirect profit

The Court held that Apotex and Teva were not entitled to claim damages for lost opportunity to reinvest profits that they would have made during the section 8 liability period. The Court emphasized that that the trial judge made her determination based on the evidence before her and that there was no palpable or overriding error.

In obiter, the Court agreed with the trial judge that, as a matter of law, pre-judgment interest was the accepted method to compensate for such a loss.

Lost sales on other products (bundling)

The Court rejected Teva's claim for lost sales on other products through the practice of 'bundling'. The Court did not comment on whether such losses were compensable under section 8 of the PM(NOC) Regulations.

Link to decision(s)

Apotex Inc. v. Sanofi-Aventis et al, 2014 FCA 68

Teva Canada Limited v. Sanofi-Aventis Canada Inc. et al. 2014 FCA 67

Norton Rose Fulbright Canada LLP

Norton Rose Fulbright is a global legal practice. We provide the world's pre-eminent corporations and financial institutions with a full business law service. We have more than 3800 lawyers based in over 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.

Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.

Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.

Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright Canada LLP, Norton Rose Fulbright South Africa (incorporated as Deneys Reitz Inc) and Fulbright & Jaworski LLP, each of which is a separate legal entity, are members ('the Norton Rose Fulbright members') of Norton Rose Fulbright Verein, a Swiss Verein. Norton Rose Fulbright Verein helps coordinate the activities of the Norton Rose Fulbright members but does not itself provide legal services to clients.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.